Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
2024年8月9日 - 7:00PM
ビジネスワイヤ(英語)
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the
“Company” or “MindMed”), a clinical stage biopharmaceutical company
developing novel product candidates to treat brain health
disorders, today announced that it intends to offer and sell,
subject to market conditions, common shares and, to certain
investors, pre-funded warrants to purchase common shares in an
underwritten public offering. All of the common shares and
pre-funded warrants are being offered by MindMed.
MindMed intends to use the net proceeds from this offering to
fund the research and development of its product candidates and
working capital and general corporate purposes.
Leerink Partners and Evercore ISI are acting as the joint
bookrunning managers for the offering. RBC Capital Markets and
Oppenheimer & Co. are acting as lead managers. The offering is
subject to market conditions and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering. No distribution under the offering
shall occur in Canada or to a person resident in Canada.
The securities in the offering are being offered by the Company
pursuant to an effective shelf registration statement on Form S-3
(File No. 333-280548) that was filed with the Securities and
Exchange Commission (“SEC”) on June 28, 2024 and became effective
upon filing. The securities will be offered by means of a
prospectus supplement and accompanying prospectus relating to the
offering that form a part of the shelf registration statement. A
preliminary prospectus supplement and the accompanying prospectus
relating to and describing the terms of the offering will be filed
with the SEC and SEDAR+ and will be available on the SEC’s website
at www.sec.gov and on SEDAR+’s website at www.sedarplus.ca. Copies
of the preliminary prospectus supplement, when available, and the
accompanying prospectus relating to the offering may be obtained,
when available, by contacting the following: Leerink Partners LLC,
Attention: Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by
email at syndicate@leerink.com, or Evercore Group L.L.C.,
Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor,
New York, NY 10055, by telephone at (888) 474-0200, or by email at
ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of the securities described
herein, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders.
MindMed trades on NASDAQ under the symbol MNMD.
Forward-Looking Statements
Certain statements in this press release related to the Company
constitute “forward-looking information” within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as “will”, “may”, “should”, “could”,
“intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”,
“potential” or “continue”, or the negative thereof or similar
variations. Forward-looking information in this press release
includes, but is not limited to, the uncertainties related to
market conditions, the intended use of proceeds, the filing of the
preliminary prospectus supplement and the accompanying prospectus
relating to the offering and the completion of the offering on the
anticipated terms or at all. There can be no assurance that this
offering will close and the Company will receive the net proceeds
therefrom. There are numerous risks and uncertainties that could
cause actual results and the Company’s plans and objectives to
differ materially from those expressed in the forward-looking
information, including market conditions and satisfaction of the
customary closing conditions for the offering. These
forward-looking statements are based on our current expectations,
estimates, forecasts and projections about the offering, our
business and the industry in which we operate and management’s
beliefs and assumptions, including the satisfaction on all
customary closing conditions and the non-occurrence of the risks
and uncertainties that are described in the filings made with the
SEC and the applicable Canadian securities regulators or other
events occurring outside of our normal course of business, and are
not guarantees of future performance or development and involve
known and unknown risks, uncertainties and other factors that are
in some cases beyond our control. Except as required by law, the
Company undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events, changes in expectations or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240808999979/en/
For Media Inquiries, please contact: media@mindmed.co
For Investor Inquiries, please contact: ir@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
過去 株価チャート
から 9 2024 まで 10 2024
Mind Medicine MindMed (NASDAQ:MNMD)
過去 株価チャート
から 10 2023 まで 10 2024